Article Per Year (5 Year)
p-Index From 2020 - 2025
0.61
P-Index
This Author published in this journals
All Journal Journal of Innovation Research and Knowledge Indonesian Journal of Pharmacology and Therapy
Bayu Prio Septiantoro
Unknown Affiliation
Humanities Economics, Econometrics & Finance Education Health Professions Immunology & microbiology Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Social Sciences

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
EFEKTIVITAS PENGGUNAAN ANTIBIOTIKA CEFEPIME DIBANDINGKAN DENGAN CEFTRIAXONE PADA PASIEN FIBRILE NEUTROPENIA ACUTE MYLOID LEUKIMIA (AML) DI RSUP Dr. KARIADI SEMARANG Muhammad Fathurrahman; Dyah A.Perwitasari; Bayu Prio Septiantoro; Putri Ayu Lestari
Journal of Innovation Research and Knowledge Vol. 4 No. 9: Februari 2025
Publisher : Bajang Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Leukemia or blood cancer is a diverse neoplastic disease, characterized by abnormal production (malignant transformation) of blood forming cells in the bone marrow and lymphoid tissue. Treatment of leukemia patients using chemotherapy. One of the side effects is Fibrile Neutropenia. Handling efforts have been done but have not provided maximum effect. Therefore there is a need for other treatments such as the use of antibiotic monotherapy. The purpose of this study was to determine the pattern of antibiotic administration in patients with AML who were diagnosed with neutropenia after induction chemotherapy and to know the effectiveness of cefepim antibiotics and ceftriaxone for treating neutropenic fever in AML after induction chemotherapy at RSUP Dr. Kariadi Semarang.The research method used was a retrospective cohort study based on primary data from the patient's medical record. The study was conducted by tracing data on medical records of patients at RSUP Dr. Kariadi Semarang analysis can be carried out using independent t test.The results showed 47 fibrile neutropenia patients who met the inclusion criteria. The mortality rate of cefepime antibiotics was 17.39% and ceftriaxone was 16.67%. The life expectancy of cefepime antibiotics was 82.61% and ceftriaxone was 83.33%. The antibiotic culture showed that 16.67% was resistant to cefepime antibiotic and 43.48% was resistant to ceftriaxone. 56.52% are still sensitive to Ceftriaxon and 83.33% are still sensitive to Cefepime. The ANC level has a significant difference (P-value of < 0.05), while in the analysis of decreased body temperature There is also a significant difference (P-value of < 0.05).From these results it can be concluded that cefepime antibiotics are more effective than ceftriaxone antibiotics in patients with AML fibrile neutripenia.
The quality of life (QoL) of advanced stage lung adenocarcinoma patients receiving afatinib at Dr. Sardjito General Hospital, Yogyakarta Bayu Prio Septiantoro; Retno Murwanti; Dyah Aryani Perwitasari; Mustofa
Indonesian Journal of Pharmacology and Therapy Vol 6 No 2 (2025)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.20381

Abstract

Lung cancer has the highest mortality rate of all cancers. In its advanced stages, this disease is associated with poor survival rates and quality of life. The most common subtype of lung cancer is adenocarcinoma which is frequently associated with mutations in the epidermal growth factor receptor (EGFR), a protein crucialfor cell proliferation. The presence of EGFR mutations plays a key role in targeted therapy using tyrosine kinase inhibitors (TKIs). Afatinib is a second-generation TKI that offers several advantages over the first-generation. Afatinib is effective against complex and uncommon EGFR mutations, making it a commonly usedoption for patients with lung adenocarcinoma. However, afatinib is also associated with a higher incidence of adverse drug reactions (ADRs) compared to other TKIs, which may impact therapeutic outcomes. This study aimed to assess the quality of life (QoL) of advanced lung adenocarcinoma patients with EGFR mutations andthe prevalence of ADRs associated with afatinib treatment at Dr. Sardjito General Hospital in Yogyakarta. The study employed an observational cross-sectional design. Prospective data collection was conducted for two months, from January to February 2025 at the Oncology Department following ethical approval. A totalof 15 patients were enrolled in this study. The most commonly identified ADRs were acne (45%), diarrhea (20%), paronychia (20%), and oral mucositis (15%). The mean QoL scores was 81.38 ± 10.01 for the functional scale, 15.93 ± 8.48 for the symptom scale, and 72.78 ± 19.53 for global health status.
Co-Authors Dyah A.Perwitasari Dyah Aryani Perwitasari Fredrick Dermawan Purba Marwin Marwin Muhammad Fathurrahman Mustofa Mustofa Putri Ayu Lestari Retno Murwanti Susan Fitri Candradewi